Tin tức & Cập nhật
Xem bài viết Dược
Xem

Tislelizumab improves survival in advanced gastric/gastro-oesophageal junction adenocarcinoma
First-line treatment with tislelizumab plus chemotherapy for advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma yields better overall survival and an acceptable safety profile compared with chemotherapy plus placebo in patients with a programmed death-ligand 1 (PD-L1) tumour area positivity (TAP) score of ≥5 percent, a study has shown.

Testosterone therapy in women may lower risks of MACE, breast cancer
Women on testosterone therapy (TTh) show a lower risk of major adverse cardiac events (MACE) than matched controls, while postmenopausal women have a comparable MACE risk and a similar or significantly reduced risk of breast cancer on age-based subanalysis, reports a study.

Low-dose aspirin for AMD prevention? ASPREE data show no benefit
Use of aspirin at 100 mg per day proved unsuccessful at reducing the incidence of age-related macular degeneration (AMD) in a large cohort of older healthy individuals, according to medium-term data from the AMD substudy of the Aspirin in Reducing Events in the Elderly (ASPREE) trial.

Arginine depletion plus chemo ups survival in rare lung cancer
In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.





